Developing a dengue vaccine: progress and future challenges (Q38201151)

30 August 2017

Developing a dengue vaccine: progress and future challenges (English)

1 reference

30 August 2017

0 references

Stephen J Thomas

1

1 reference

PubMed ID

24689974

30 August 2017

language of work or name

English

0 references

publication date

1 April 2014

1 reference

Annals of the New York Academy of Sciences

30 August 2017

1 reference

30 August 2017

1323

1 reference

30 August 2017

140-159

1 reference

The global distribution and burden of dengue

30 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Economic and disease burden of dengue in Southeast Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Total economic cost and burden of dengue in Nicaragua: 1996-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

High household economic burden caused by hospitalization of patients with severe dengue fever cases in Can Tho province, Vietnam

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Economic cost of dengue in Puerto Rico

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

The economic burden of dengue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Economic impact of dengue illness in the Americas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Economic value of dengue vaccine in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Health economics of dengue: a systematic literature review and expert panel's assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Economic burden of dengue infections in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

The health and economic impact of dengue in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Prevalence of dengue virus infection in US travelers who have lived in or traveled to dengue-endemic countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Acute and potentially life-threatening tropical diseases in western travelers--a GeoSentinel multicenter study, 1996-2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Infectious disease emergencies in returning travelers: special reference to malaria, dengue fever, and chikungunya

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Imported malaria and dengue fever in returned travelers in Japan from 2005 to 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue: A reemerging concern for travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue and chikungunya in travelers: recent updates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue and chikungunya infections in travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue and US military operations from the Spanish-American War through today

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue fever in US military personnel in Haiti

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue, Urbanization and Globalization: The Unholy Trinity of the 21(st) Century

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue prevention and 35 years of vector control in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Stable introduction of a life-shortening Wolbachia infection into the mosquito Aedes aegypti

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Wolbachia and the biological control of mosquito-borne disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Field performance of engineered male mosquitoes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

21 January 2018

Ecology. Mosquito trials

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue Virus Serotype 2 from a Sylvatic Lineage Isolated from a Patient with Dengue Hemorrhagic Fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Immune markers and correlates of protection for vaccine induced immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue viral RNA levels in peripheral blood mononuclear cells are associated with disease severity and preexisting dengue immune status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue: defining protective versus pathologic immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Antibody-enhanced dengue virus infection in primate leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

How innate immune mechanisms contribute to antibody-enhanced viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Report of an NIAID workshop on dengue animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Animal models of dengue virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

New generation humanized mice for virus research: comparative aspects and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Human immune responses and potential for vaccine assessment in humanized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Further Experiments in the Etiology of Dengue Fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Experimental studies on dengue. I. Isolation, identification and modification of the virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Evaluation of dengue virus strains for human challenge studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Sonographic findings of healthy volunteers infected with dengue virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue Plaque Reduction Neutralization Test (PRNT) in Primary and Secondary Dengue Virus Infections: How Alterations in Assay Conditions Impact Performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue virus neutralization in cells expressing Fc gamma receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Neutralization of dengue virus in the presence of Fc receptor-mediated phagocytosis distinguishes serotype-specific from cross-neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue virus neutralization is modulated by IgG antibody subclass and Fcγ receptor subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Immunogenicity of sanofi pasteur tetravalent dengue vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Comparison by flow cytometry of immune changes induced in human monocyte-derived dendritic cells upon infection with dengue 2 live-attenuated vaccine or 16681 parental strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Preparing for dengue vaccine introduction: recommendations from the 1st dengue v2V International Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue vaccines regulatory pathways: a report on two meetings with regulators of developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

"Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization Technical Consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

The micro-focus reduction neutralization test for determining dengue and Japanese encephalitis neutralizing antibodies in volunteers vaccinated against dengue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Live attenuated tetravalent dengue vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Study of bivalent dengue vaccine in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue virus premembrane and membrane proteins elicit a protective immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Development of a live attenuated dengue virus vaccine using reverse genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Epidemiology of dengue virus in Iquitos, Peru 1999 to 2005: interepidemic and epidemic patterns of transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue vaccine prospects: a step forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Determining genetic stabilities of chimeric dengue vaccine candidates based on dengue 2 PDK-53 virus by sequencing and quantitative TaqMAMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Protection against Japanese encephalitis by inactivated vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Development of dengue DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Circulation of different lineages of dengue virus type 2 in Central America, their evolutionary time-scale and selection pressure analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

The history and evolution of human dengue emergence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Microevolution and virulence of dengue viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Efficacy of tetravalent dengue vaccine in Thai schoolchildren - Authors' reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Antibodies determine virulence in dengue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Discrepancy in Dengue Virus Neutralizing Antibody Titers between Plaque Reduction Neutralizing Tests with Fc Receptor (Fc R)-Negative and Fc R-Expressing BHK-21 Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

The Evolutionary Biology of Dengue Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12413

Research on dengue during World War II

21 January 2018

1 reference

21 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.4269/AJTMH.1952.1.30

Identifiers

DOI

10.1111/NYAS.12413

1 reference

30 August 2017

1 reference

PubMed ID

24689974